Archon Biosciences emerges from stealth with $20M to create tiny ‘Antibody Cages’
Archon Biosciences, a Seattle-based spinout from the lab of Nobel Prize winner David Baker, has emerged from stealth mode with $20 million in funding for a technology that uses computationally designed protein structures to treat cancer and other diseases.
“By building a modular design platform, we readily iterate and optimize each design quickly, efficiently and inexpensively, based on data that comes in,” said George Ueda, Archon’s chief technology officer and co-founder. “It’s a validated and efficient engineering framework that we employ at Archon to make better therapeutics faster. We can make two drugs for two different applications and make it easier to do both.”
Following in the footsteps of numerous spinouts from the University of Washington’s Institute for Protein Design, Archon strengthens the pipeline of homegrown innovation in Washington state.